Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

MenQuadfi Now Approved for 6‑Week‑Old Infants: A Game‑Changing Meningococcal Vaccine Milestone

MenQuadfi now protects infants as young as 6 weeks—European Commission approval backed by the MET58 trial shows robust safety and high antibody responses for early IMD protection.

Dr. Michael Chen

05/08/2026, 02:00

4 minutes to read

MTTO Announces Board Expansion: New Director Natalia Shuman Boosts Governance and Compliance Focus

MTTO announces a new independent director, boosts governance and regulatory expertise, and notes a board member’s modest share sale – a strategic move for future growth.

Dr. Michael Chen

05/08/2026, 01:50

4 minutes to read

Neurocrine Biosciences Q2 2026: Strong Revenue, Upgraded Guidance & Corporate Moves Boost Investor Confidence

Neurocrine Biosciences posts Q2 2026 growth, Ingrezza revenue boost, and strategic equity moves—highlighting solid performance and a bullish outlook.

Dr. Michael Chen

03/08/2026, 00:56

2 minutes to read

MERCK KGAA Surges: Strong Q4 Earnings, AI-Driven Growth & Pipeline Highlights

MERCK KGAA beats earnings estimates yet faces tech‑driven valuation pressure, as investors weigh its oncology, immunology, and COVID‑19 pipeline amid semiconductor market shifts.

Dr. Michael Chen

02/08/2026, 18:53

4 minutes to read

Novo Nordisk Shares Fall 10% as Ziltivekimab Phase‑III Trial Fails to Cut Heart Events

New Nordisk shares fell as the Phase‑III trial of Ziltivekimab failed to reduce cardiovascular events, highlighting the challenges of anti‑inflammatory heart therapies and the company’s reliance on core GLP‑1 products.

Dr. Michael Chen

01/08/2026, 22:33

3 minutes to read

United Therapeutics CEO Trades Shares Under SEC‑Compliant Plan – Investor & Pipeline Insights

United Therapeutics’ July 29 Form 4 shows CEO trades within SEC‑approved windows while the company advances inhaled prostacyclin, CRISPR‑AAV PAP, and a lung‑cancer immunotherapy combo.

Dr. Michael Chen

01/08/2026, 10:00

5 minutes to read

Pfizer’s Litfulo Passes Phase‑III, and XFG‑Targeted COVID Vaccine Earns EU Approval

Pfizer’s Litfulo phase‑III wins and new XFG‑variant COVID‑19 vaccine launch boost its dermatology and vaccinology portfolios with strong efficacy and safety.

Dr. Michael Chen

31/07/2026, 23:37

3 minutes to read

J&J Faces Litigation Fallout as FDA Accelerates Rybrevant, Boosting Oncology & IBD Growth

Explore how Johnson & Johnson’s ovarian‑cancer settlement and Rybrevant’s FDA priority review impact its stock, while new IBD therapy shows promise for future growth.

Dr. Michael Chen

31/07/2026, 22:47

4 minutes to read

Biogen Q2 2026: Revenue Surges, Apellis Integration, and 4‑5% Growth Outlook

Biogen’s Q2 2026 results show modest revenue growth and a new earnings outlook, driven by Apellis acquisitions and strong Leqembi sales, hinting at a diversified future.

Dr. Michael Chen

30/07/2026, 15:48

5 minutes to read

Incyte Q2 2026 Earnings Surge: Revenue +19%, Share Price Hits 52-Week High

Incyte’s Q2 2026 earnings boost revenue & earnings, driving stock to a 52‑week high thanks to Jakafi growth, Opzelura CMS gains and a strong pipeline outlook.

Dr. Michael Chen

30/07/2026, 10:58

4 minutes to read

Newer articles Older articles